How deadly is Prostate cancer?

Cé chomh marfach is atá ailse prostata?

Is é ailse próstatach an dara ailse is coitianta i bhfear ar fud an domhain, le meastachán 1.276 milliún cás nua a tuairiscíodh i 2018, a léiríonn 7.1% de na cásanna ailse go léir i bhfear.

Tá an ráta báis le haghaidh ailse próstatach ard freisin, le 37,005 bás measta ar fud an domhain i 2018.

Mar sin féin, athraíonn an ráta báis go mór de réir réigiúin, agus is é an Afraic Thiar an cúigiú riosca is airde le haghaidh báis ailse próstatach ar domhan, agus is é an Nigéir an daonra agus an geilleagar is mó sa réigiún seo.

Sa Nigéir, is é ailse próstatach an ailse is coitianta agus is marfach d'fhir, le 32.8 cás measta agus 16.3 bás in aghaidh na 100,000 fear.

Tá sé seo níos mó ná dúbailte ná an ráta báis i Meiriceá Thuaidh.

Cuidíonn fionraí déanach an ghalair, acmhainní teoranta le haghaidh scagadh agus braite, agus laghdú ar dhoiciméadú agus tuairisciú cásanna leis an ráta báis ard sa Nigéir.

Sna Stáit Aontaithe, is é ailse próstatach an dara cúis is coitianta de bhás ailse i bhfear, le thart ar 40,0000 fear ag bás ón galar gach bliain.

Tá an ráta báis ó ailse próstatach ag laghdú go mall ó thús na 1990í, ach tá sé fós ina ábhar imní suntasach sláinte.

Go ginearálta, is galar marfach é ailse próstatach, go háirithe i réigiúin nach bhfuil rochtain teoranta acu ar chúram leighis agus ar acmhainní scagadh.

Mar sin féin, is féidir leis an bhrath agus an chóireáil luath torthaí a fheabhsú go suntasach agus rátaí báis a laghdú.

Tagairtí

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

Diúltú freagrachta: leighis

Cuirtear an suíomh gréasáin seo ar fáil chun críocha oideachais agus faisnéise amháin agus ní sholáthraíonn sé comhairle leighis nó seirbhísí gairmiúla.

Níor cheart an t-eolas a chuirtear ar fáil a úsáid chun fadhb sláinte nó galar a dhiagnóisiú nó a chóireáil, agus ba cheart dóibh siúd atá ag lorg comhairle leighis phearsanta dul i gcomhairle le dochtúir ceadúnaithe.

Tabhair faoi deara le do thoil go bhfuil an líonra néarónach a ghineann freagraí ar na ceisteanna, míchruinn go háirithe nuair a bhaineann sé le hábhar uimhriúil. Mar shampla, líon na ndaoine a ndearnadh diagnóis orthu le galar ar leith.

Déan comhairle do dhochtúir nó do sholáthraí sláinte cáilithe eile i gcónaí maidir le riocht leighis. Ná déan neamhaird ar chomhairle leighis ghairmiúil ná déileáil leis mar gheall ar rud éigin a léigh tú ar an suíomh Gréasáin seo. Má cheapann tú go bhféadfadh éigeandáil leighis a bheith agat, glaoigh ar 911 nó téigh go dtí an seomra éigeandála is gaire láithreach. Ní chruthaíonn an suíomh Gréasáin seo ná a úsáid aon chaidreamh dochtúir-othar. Ní dhéanann BioMedLib ná a chuid fostaithe, ná aon ranníocóir leis an suíomh Gréasáin seo aon ionadaíochtaí, sainráite nó intuigthe, maidir leis an bhfaisnéis a sholáthraítear anseo ná a úsáid.

Diúltú freagrachta: cóipchirt

Soláthraíonn an Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (an DMCA) aisíocaíocht do úinéirí cóipchirt a chreideann go sáraíonn ábhar atá le feiceáil ar an Idirlíon a gcearta faoi dhlí cóipchirt na Stát Aontaithe.

Má chreideann tú go dea-chreidimh go sáraíonn aon ábhar nó ábhar a chuirtear ar fáil i ndáil lenár suíomh Gréasáin nó lenár seirbhísí do chóipcheart, féadfaidh tú (nó do ghníomhaire) fógra a sheoladh chugainn ag iarraidh an t-ábhar nó an t-ábhar a bhaint, nó rochtain air a bhac.

Ní mór fógraí a sheoladh i scríbhinn trí ríomhphost (féach an rannán "Contact" le haghaidh seoladh ríomhphoist).

Éilíonn an DMCA go gcuimsíonn do fhógra faoi shárú cóipchirt líomhain an fhaisnéis seo a leanas: (1) cur síos ar an saothar cóipchirt atá ina ábhar don shárú líomhain; (2) cur síos ar an ábhar líomhain atá ag sárú líomhain agus faisnéis leordhóthanach chun ligean dúinn an t-ábhar a aimsiú; (3) faisnéis teagmhála duit, lena n-áirítear do sheoladh, uimhir theileafóin agus seoladh ríomhphoist; (4) ráiteas uait go bhfuil creideamh maith agat nach bhfuil an t-ábhar ar an mbealach a bhfuil gearán á dhéanamh air údaraithe ag úinéir cóipchirt, nó a ghníomhaire, nó ag oibriú aon dlí;

(5) ráiteas uait, arna shíniú faoi phionós perjury, go bhfuil an t-eolas sa fhógra cruinn agus go bhfuil an t-údarás agat na cóipchearta a éilítear a shárú a fhorfheidhmiú;

agus (6) síntiús fisiciúil nó leictreonach úinéir an chóipchirt nó duine údaraithe chun gníomhú thar ceann úinéir an chóipchirt.

D'fhéadfadh moill a bheith ar phróiseáil do ghearán mura gcuirfidh tú an t-eolas thuas go léir san áireamh.

Cumarsáid

Seol ríomhphost dúinn le haon cheist / moladh le do thoil.

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.